RT @ASBMR: The objective of a new #JBMR clinical trial was to evaluate the potential therapeutic advantage of Ca-Cit in comparison with calcium carbonate in HypoPT, on nephrolithiasis risk factors #ASBMR #openaccess #freetoread @WileyBiomedical https://t.co/zvEGs8Mggn https://t.co/tmSpGHaIvT
RT @ASBMR: The objective of a new #JBMR clinical trial was to evaluate the potential therapeutic advantage of Ca-Cit in comparison with calcium carbonate in HypoPT, on nephrolithiasis risk factors #ASBMR #openaccess #freetoread @WileyBiomedical https://t.co/zvEGs8Mggn https://t.co/tmSpGHaIvT
— Gaston Ramirez (@GastonR48222321) Jun 30, 2022
from Twitter https://twitter.com/GastonR48222321
June 30, 2022 at 08:15AM
Comentarios
Publicar un comentario